Merck Launches 11th Global Phase III Trial of Lurcanostatuzumab for Platinum-Sensitive Recurrent Ovarian Cancer

▎Armstrong

On February 13, 2025, MSD registered a Phase III clinical trial, TroFuse-022, on Clinicaltrials.gov for its new Trop2 ADC drug, Rucosartuzumab (MK-2870, SKB264), to treat patients with platinum-sensitive recurrent ovarian cancer. This marks the 11th global Phase III clinical trial MSD has initiated around Rucosartuzumab.

TroFuse-022 plans to enroll 770 patients with platinum-sensitive, metastatic ovarian cancer who have undergone second-line platinum-based chemotherapy, with preliminary completion expected by 2030.

MSD has cumulatively initiated 11 global Phase III clinical trials around Lecanemab, covering multiple tumor types including non-small cell lung cancer, endometrial cancer, breast cancer, gastric cancer, cervical cancer, and ovarian cancer.

• Trofuse-004: Previously treatedEGFR mutation or other mutations in advanced or metastatic non-squamous non-small cell lung cancer;

• Trofuse-005: Previously treated with platinum-based chemotherapy and immunotherapyEndometrial cancer;

• Trofuse-007：Metastatic non-small cell lung cancer with high PD-L1 expression (TPS≥50%);

• Trofuse-009：Advanced non-squamous non-small cell lung cancer with EGFR mutation, progressed after EGFR-TKI treatment;

• Trofuse-010: InoperableLocally advanced or metastatic HR+/HER2- breast cancer;

• Trofuse-012: Adjuvant treatment for triple-negative breast cancer that did not achieve pathological complete response after previous neoadjuvant therapy and surgery;

• Trofuse-015：Advanced or metastatic gastric esophageal adenocarcinoma;

• Trofuse-019: Adjuvant treatment for non-small cell lung cancer that has not achieved pathological complete response after surgery;

• Trofuse-020: Recurrent or metastatic cervical cancer;

• Trofuse-022: Platinum-based chemotherapy-sensitive recurrent ovarian cancer;

• Trofuse-023: Metastatic squamous non-small cell lung cancer.

Summary

Since October 2023, MSD has intensively launched 11 global Phase III clinical trials of Lutrisocept, covering multiple types of tumors.As MSD mentioned at ESMO2023, lutetium (177Lu) luclotide has become a key foothold in its oncology field and one of the important entry points for clinical breakthroughs.MSDFull PowerTo advance the clinical development of Lecanemab, it is necessary to cover a broader range of cancer types and actively expand from later-line to front-line treatment.